REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01627691
First received: June 5, 2012
Last updated: January 14, 2014
Last verified: January 2014

June 5, 2012
January 14, 2014
October 2012
April 2013   (final data collection date for primary outcome measure)
  • Primary Device Performance Endpoint: Mean aortic valve pressure gradient at 30 days post implant procedure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    Mean aortic valve pressure gradient at 30 days post implant procedure as measured by echocardiography and assessed by an independent core laboratory.
  • Primary Safety Endpoint: All-cause mortality at 30 days post implant procedure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    All-cause mortality at 30 days post implant procedure
Same as current
Complete list of historical versions of study NCT01627691 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance
REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance

The purpose of this study is to evaluate the safety and performance of the Lotus™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with severe calcific aortic stenosis who are considered high risk for surgical valve replacement.

Not Provided
Interventional
Phase 3
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Transcatheter Aortic Valve Replacement
Device: Lotus Valve System
  • bioprosthetic bovine pericardial aortic valve
  • delivery system
Experimental: Lotus Valve System
Patients enrolled will receive the Lotus Valve.
Intervention: Device: Lotus Valve System
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
120
March 2018
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is ≥70 years of age
  • Subject has documented calcific native aortic valve stenosis
  • Subject has a documented aortic annulus size between ≥19 and ≤27 mm based on pre-procedure diagnostic imaging
  • Symptomatic aortic valve stenosis with NYHA Functional Class ≥ II
  • Subject is considered high risk for surgical valve replacement
  • Heart team assessment that the subject is likely to benefit from valve replacement.
  • Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent.
  • Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits.

Exclusion Criteria:

  • Subject has a congenital unicuspid or bicuspid aortic valve.
  • Subject with an acute myocardial infarction within 30 days of the index procedure
  • Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months, or has any permanent neurologic defect prior to study enrollment.
  • Subject is on dialysis or has serum creatinine level >3.0 mg/dL or 265 µmol/L.
  • Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic ring in any position.
  • subject cannot have more than moderate mitral, aortic or tricuspid regurgitation
  • Subject has a need for emergency surgery for any reason.
  • Subject has a history of endocarditis within 12 months of index procedure or evidence of an active systemic infection or sepsis.
  • Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.
  • Subject has low Hgb, platelet count or >700,000 cells/mm3, or low white blood cell count.
  • Subject requires chronic anticoagulation therapy and cannot tolerate concomitant therapy with either aspirin or clopidogrel/ticlopidine
  • Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3 months, other bleeding diathesis or coagulopathy or will refuse transfusions.
  • Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin, nickel, tantalum, titanium, or polyurethanes.
  • Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrollment.
  • Subject has hypertrophic obstructive cardiomyopathy.
  • Subject has any therapeutic invasive cardiac procedure within 30 days prior to the index procedure (except for pacemaker implantation which is allowed).
  • Subject has untreated coronary artery disease.
  • Subject has documented left ventricular ejection fraction <30%.
  • Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices.
  • Subject has severe peripheral vascular disease or symptomatic carotid or vertebral disease.
  • Narrow Femoral artery lumen precludes the use of either Lotus device size, or severe iliofemoral tortuosity or calcification that would prevent safe placement of the introducer sheath.
  • Current problems with substance abuse (e.g., alcohol, etc.).
  • Subject is participating in another investigational drug or device study that has not reached its primary endpoint.
  • Patient has preexisting untreated conduction system disorder that requires new pacemaker implantation.
Both
70 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Australia,   France,   Germany,   United Kingdom
 
NCT01627691
TP3687, TP3687
Yes
Boston Scientific Corporation
Boston Scientific Corporation
Not Provided
Principal Investigator: Ian Meredith, Professor Monash Medical Centre
Boston Scientific Corporation
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP